Resistance to platinum-based cancer drugs: a special focus on epigenetic mechanisms

References

• 1. Organización Mundial de la Salud. Cáncer. (2018). https//www.who.int/es/news-room/fact-sheets/detail/cancer
  Google Scholar
• 2. Wilting RH, Dannenberg J-H. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist. Updat. 15(1–2), 21–38 (2012).
  Medline CASGoogle Scholar
• 3. Rocha C, Silva M, Quinet A, Cabral-Neto J, Menck C. DNA repair pathways and cisplatin resistance: an intimate relationship. Clinics. 73(Suppl. 1), 1–10 (2018).
  Google Scholar
• 4. Easwaran H, Tsai H, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol. Cell. 54(5), 716–727 (2014).
  Medline CASGoogle Scholar
• 5. Ponnusamy L, Mahalingaiah PKS, Chang Y-W, Singh KP. Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer. Cancer Drug Resist. 2, 297–312 (2019).
  Google Scholar
• 6. Allis CD, Jenuwein T. The molecular hallmarks of epigenetic control. Nat. Rev. Genet. 17(8), 487–500 (2016).
  Medline CASGoogle Scholar
• 7. Peng L, Zhong X. Epigenetic regulation of drug metabolism and transport. Acta Pharm. Sin. B. 5(2), 106–112 (2015).
  MedlineGoogle Scholar
• 8. Ivanov M, Barragan I, Ingelman-Sundberg M. Epigenetic mechanisms of importance for drug treatment. Trends Pharmacol. Sci. 35(8), 384–396 (2014).
  Medline CASGoogle Scholar
• 9. Redmond KM. Resistance mechanisms to cancer chemotherapy. Front. Biosci. 13(13), 5138 (2008).
  Medline CASGoogle Scholar
• 10. Zhou J, Kang Y, Chen L et al. The drug-resistance mechanisms of five platinum-based antitumor agents. Front. Pharmacol. 11, 1–17 (2020).
  Medline CASGoogle Scholar
• 11. Astolfi L, Ghiselli S, Guaran V et al. Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: a retrospective evaluation. Oncol. Rep. 29(4), 1285–1292 (2013).
  Medline CASGoogle Scholar
• 12. Jain A, Jahagirdar D, Nilendu P, Sharma NK. Molecular approaches to potentiate cisplatin responsiveness in carcinoma therapeutics. Expert Rev. Anticancer Ther. 17(9), 815–825 (2017).
  Medline CASGoogle Scholar
• 13. Reyes ME, de La Fuente M, Hermoso M, Ili CG, Brebi P. Role of CC chemokines subfamily in the platinum drugs resistance promotion in cancer. Front. Immunol. 11, 1–9 (2020).
  MedlineGoogle Scholar
• 14. Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long noncoding RNAs in cancer. Genomics, Proteomics Bioinforma. 14(1), 42–54 (2016).
  MedlineGoogle Scholar
• 15. Kacevska M, Ivanov M, Ingelman-Sundberg M. Perspectives on epigenetics and its relevance to adverse drug reactions. Clin. Pharmacol. Ther. 89(6), 902–907 (2011).
  Medline CASGoogle Scholar
• 16. Brunton L, Chabner B, Knollman B. Goodman and Gilman's Las bases farmacológicas de la terapéutica. 12th Edition. McGraw Hill, México.
  Google Scholar
• 17. Li A, Song J, Lai Q et al. Hypermethylation of ATP-binding cassette B1 (ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line. Int. J. Exp. Pathol. 97(6), 412–421 (2016).
  Medline CASGoogle Scholar
• 18. Moon HH, Kim SH, Ku JL. Correlation between the promoter methylation status of ATP-binding cassette sub-family G member 2 and drug sensitivity in colorectal cancer cell lines. Oncol. Rep. 35(1), 298–306 (2016).
  Medline CASGoogle Scholar
• 19. Zhang Y, Qu X, Jing W et al. GSTP1 determines cis-platinum cytotoxicity in gastric adenocarcinoma MGC803 cells: regulation by promoter methylation and extracellular regulated kinase signaling. Anticancer Drugs 20(3), 208–214 (2009).
  Medline CASGoogle Scholar
• 20. Lin H, Yang G, Yu J et al. KDM5c inhibits multidrug resistance of colon cancer cell line by down-regulating ABCC1. Biomed. Pharmacother. 107, 1205–1209 (2018).
  Medline CASGoogle Scholar
• 21. Lan WG, Xu DH, Xu C et al. Silencing of long noncoding RNA ANRIL inhibits the development of multidrug resistance in gastric cancer cells. Oncol. Rep. 36(1), 263–270 (2016).
  Medline CASGoogle Scholar
• 22. Sun MY, Zhu JY, Zhang CY et al. Autophagy regulated by lncRNA HOTAIR contributes to the cisplatin-induced resistance in endometrial cancer cells. Biotechnol. Lett. 39(10), 1477–1484 (2017).
  Medline CASGoogle Scholar
• 23. Zhang XW, Bu P, Liu L, Zhang XZ, Li J. Overexpression of long noncoding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Biochem. Biophys. Res. Commun. 462(3), 227–232 (2015).
  Medline CASGoogle Scholar
• 24. Cheng FH, Zhao ZS, Liu WD. Long noncoding RNA ROR regulated ABCB1 to induce cisplatin resistance in osteosarcoma by sponging miR-153-3p. Eur. Rev. Med. Pharmacol. Sci. 23(17), 7256–7265 (2019).
  MedlineGoogle Scholar
• 25. Wu X, Zheng Y, Han B, Dong X. Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361. Biomed. Pharmacother. 99, 832–838 (2018).
  Medline CASGoogle Scholar
• 26. Zheng ZG, Xu H, Suo SS et al. The essential role of H19 contributing to cisplatin resistance by regulating glutathione metabolism in high-grade serous ovarian cancer. Sci. Rep. 6, 1–12 (2016).
  MedlineGoogle Scholar
• 27. Lu C, Shan Z, Li C, Yang L. MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp. Biomed. Pharmacother. 86, 450–456 (2017).
  Medline CASGoogle Scholar
• 28. Hao GJ, Ding Y-H, Wen H et al. Attenuation of deregulated miR-369-3p expression sensitizes non-small-cell lung cancer cells to cisplatin via modulation of the nucleotide sugar transporter SLC35F5. Biochem. Biophys. Res. Commun. 488(3), 501–508 (2017).
  Medline CASGoogle Scholar
• 29. Yang L, Li N, Wang H, Jia X, Wang X, Luo J. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Oncol. Rep. 28(2), 592–600 (2012).
  Medline CASGoogle Scholar
• 30. Ma Y, Li X, Cheng S, Wei W, Li Y. MicroRNA-106a confers cisplatin resistance in non-small-cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1. Mol. Med. Rep. 11(1), 625–632 (2015).
  Medline CASGoogle Scholar
• 31. Yu Z, Cao W, Ren Y, Zhang Q, Liu J. ATPase copper transporter A, negatively regulated by miR-148a-3p, contributes to cisplatin resistance in breast cancer cells. Clin. Transl. Med. 10(1), 57–73 (2020).
  MedlineGoogle Scholar
• 32. Dong Z, Zhong Z, Yang L, Wang S, Gong Z. MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small-cell lung cancer cells by regulating the drug transporter ABCB9. Cancer Lett. 343(2), 249–257 (2014).
  Medline CASGoogle Scholar
• 33. Pei K, Zhu JJ, Wang CE, Xie QL, Guo JY. MicroRNA-185-5p modulates chemosensitivity of human non-small-cell lung cancer to cisplatin via targeting ABCC1. Eur. Rev. Med. Pharmacol. Sci. 20(22), 4697–4704 (2016).
  Medline CASGoogle Scholar
• 34. Zhan M, Zhao X, Wang H et al. miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1. Tumor Biol. 37(8), 10553–10562 (2016).
  Medline CASGoogle Scholar
• 35. Zhou H, Lin C, Zhang Y et al. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression. Cell Prolif. 50(3), 1–10 (2017).
  Google Scholar
• 36. Song L, Li Y, Li W, Wu S, Li Z. MiR-495 enhances the sensitivity of non-small-cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A). J. Cell. Biochem. 115(7), 1234–1242 (2014).
  Medline CASGoogle Scholar
• 37. Chen S, Jiao JW, Sun KX, Zong ZH, Zhao Y. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs. Drug Des. Devel. Ther. 9, 5225–5235 (2015).
  Medline CASGoogle Scholar
• 38. Shi L, Chen ZG, Li-li Wu et al. miR-340 reverses cisplatin resistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway. Asian Pacific J. Cancer Prev. 15(23), 10439–10444 (2014).
  MedlineGoogle Scholar
• 39. Zong C, Wang J, Shi TM. MicroRNA 130b enhances drug resistance in human ovarian cancer cells. Tumor Biol. 35(12), 12151–12156 (2014).
  Medline CASGoogle Scholar
• 40. Lin C, Xie L, Lu Y, Hu Z, Chang J. MiR-133b reverses cisplatin resistance by targeting GSTP1 in cisplatin-resistant lung cancer cells. Int. J. Mol. Med. 41(4), 2050–2058 (2018).
  Medline CASGoogle Scholar
• 41. Kacevska M, Ivanov M, Ingelman-Sundberg M. Epigenetic-dependent regulation of drug transport and metabolism: an update. Pharmacogenomics 13(12), 1373–1385 (2012).
  CASGoogle Scholar
• 42. Tang X, Chen S. Epigenetic regulation of cytochrome P450 enzymes and clinical implication. Curr. Drug Metab. 16(2), 86–96 (2015).
  Medline CASGoogle Scholar
• 43. Guo M, Peng Y, Gao A, Du C, Herman JG. Epigenetic heterogeneity in cancer. Biomark. Res. 7(1), 23 (2019).
  MedlineGoogle Scholar
• 44. Kaur G, Gupta SK, Singh P, Ali V, Kumar V, Verma M. Drug-metabolizing enzymes: role in drug resistance in cancer. Clin. Transl. Oncol. 22(10), 1667–1680 (2020).
  Medline CASGoogle Scholar
• 45. Choi Y, Yu A-M. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr. Pharm. Des. 20(5), 793–807 (2014).
  Medline CASGoogle Scholar
• 46. Mariño-Ramírez L, Kann MG, Shoemaker BA, Landsman D. Histone structure and nucleosome stability. Expert Rev. Proteomics. 2(5), 719–729 (2005).
  Medline CASGoogle Scholar
• 47. Chi P, Allis CD, Wang GG. Covalent histone modifications – miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 10(7), 457–469 (2010).
  Medline CASGoogle Scholar
• 48. Zhong X, Leeder JS. Epigenetic regulation of ADME-related genes: focus on drug metabolism and transport. Drug Metab. Dispos. 41(10), 1721–1724 (2013).
  Medline CASGoogle Scholar
• 49. O'Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front. Endocrinol. (Lausanne). 9, 1–12 (2018).
  MedlineGoogle Scholar
• 50. Ambros V. The functions of animal microRNAs. Nature 431(7006), 350–355 (2004).
  Medline CASGoogle Scholar
• 51. Gebert LFR, MacRae IJ. Regulation of microRNA function in animals. Nat. Rev. Mol. Cell Biol. 20(1), 21–37 (2019).
  Medline CASGoogle Scholar
• 52. Letelier P, García P, Leal P et al. miR-1 and miR-145 act as tumor suppressor microRNAs in gallbladder cancer. Int. J. Clin. Exp. Pathol. 7(5), 1849–1867 (2014).
  MedlineGoogle Scholar
• 53. Riquelme I, Letelier P, Riffo-Campos A, Brebi P, Roa J. Emerging role of miRNAs in the drug resistance of gastric cancer. Int. J. Mol. Sci. 17(3), 424 (2016).
  MedlineGoogle Scholar
• 54. Mercer TR, Dinger ME, Mattick JS. Long noncoding RNAs: insights into functions. Nat. Rev. Genet. 10(3), 155–159 (2009).
  Medline CASGoogle Scholar
• 55. Wang Q, Wang P, Zhang L et al. Epigenetic regulation of RIP3 suppresses necroptosis and increases resistance to chemotherapy in nonsmall cell lung cancer. Transl. Oncol. 13(2), 372–382 (2020).
  MedlineGoogle Scholar
• 56. Zhao J, Xue X, Fu W et al. Epigenetic activation of FOXF1 confers cancer stem cell properties to cisplatin-resistant non-small-cell lung cancer. Int. J. Oncol. 56(5), 1083–1092 (2020).
  Medline CASGoogle Scholar
• 57. Hayashi M, Guida E, Inokawa Y et al. GULP1 regulates the NRF2-KEAP1 signaling axis in urothelial carcinoma. Sci. Signal. 13(645), eaba0443 (2020).
  Medline CASGoogle Scholar
• 58. Wang X, Ghareeb WM, Zhang Y et al. Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin-based chemotherapy resistance of colorectal cancer. J. Cell. Physiol. 234(10), 18180–18191 (2019).
  Medline CASGoogle Scholar
• 59. Fujiyoshi S, Honda S, Minato M et al. Hypermethylation of CSF3R is a novel cisplatin resistance marker and predictor of response to postoperative chemotherapy in hepatoblastoma. Hepatol. Res. 50(5), 598–606 (2020).
  Medline CASGoogle Scholar
• 60. Peng Y, Wang L, Wu L, Zhang L, Nie G, Guo M. Methylation of SLFN11 promotes gastric cancer growth and increases gastric cancer cell resistance to cisplatin. J. Cancer. 10(24), 6124–6134 (2019).
  Medline CASGoogle Scholar
• 61. Tian H, Yan L, Xiao-fei L, Hai-yan S, Juan C, Shan K. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer. Clin. Epigenetics. 11(1), 153 (2019).
  MedlineGoogle Scholar
• 62. Yang S, Ahn S, Kim J. 3-Oxoacid CoA transferase 1 as a therapeutic target gene for cisplatin-resistant ovarian cancer. Oncol. Lett. 15(2), 2611–2618 (2017).
  MedlineGoogle Scholar
• 63. Ha Y-N, Sung HY, Yang S-D, Chae YJ, Ju W, Ahn J-H. Epigenetic modification of α-N-acetylgalactosaminidase enhances cisplatin resistance in ovarian cancer. Korean J. Physiol. Pharmacol. 22(1), 43 (2018).
  Medline CASGoogle Scholar
• 64. Grasse S, Lienhard M, Frese S et al. Epigenomic profiling of non-small-cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance. Genome Med. 10(1), 55 (2018).
  MedlineGoogle Scholar
• 65. Kritsch D, Hoffmann F, Steinbach D et al. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer. Int. J. Cancer 141(8), 1600–1614 (2017).
  Medline CASGoogle Scholar
• 66. de Leon M, Cardenas H, Vieth E et al. Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer. Gynecol. Oncol. 142(3), 539–547 (2016).
  Medline CASGoogle Scholar
• 67. Liu D, Zhang XX, Li MC et al. C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation. Nat. Commun. 9(1739), 1–13 (2018).
  MedlineGoogle Scholar
• 68. Xu Z, Sun Y, Wang D, Sun H, Liu X. SNHG16 promotes tumorigenesis and cisplatin resistance by regulating miR-338-3p/PLK4 pathway in neuroblastoma cells. Cancer Cell Int. 20(1), 236 (2020).
  Medline CASGoogle Scholar
• 69. Li H, Ma X, Yang D, Suo Z, Dai R, Liu C. PCAT-1 contributes to cisplatin resistance in gastric cancer through epigenetically silencing PTEN via recruiting EZH2. J. Cell. Biochem. 121(2), 1353–1361 (2020).
  Medline CASGoogle Scholar
• 70. Lin S, Zhang R, An X et al. LncRNA HOXA-AS3 confers cisplatin resistance by interacting with HOXA3 in non-small-cell lung carcinoma cells. Oncogenesis 8(11), 60 (2019).
  MedlineGoogle Scholar
• 71. Yu G, Zhou H, Yao W, Meng L, Lang B. lncRNA TUG1 promotes cisplatin resistance by regulating CCND2 via epigenetically silencing miR-194-5p in bladder cancer. Mol. Ther. - Nucleic Acids 16, 257–271 (2019).
  CASGoogle Scholar
• 72. Liu S, Lei H, Luo F, Li Y, Xie L. The effect of lncRNA HOTAIR on chemoresistance of ovarian cancer through regulation of HOXA7. Biol. Chem. 399(5), 485–497 (2018).
  Medline CASGoogle Scholar
• 73. Fang Z, Zhao J, Xie W, Sun Q, Wang H, Qiao B. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression. Cancer Med. 6(12), 2897–2908 (2017).
  Medline CASGoogle Scholar
• 74. Shi X, Xiao L, Mao X et al. miR-205-5p mediated downregulation of PTEN contributes to cisplatin resistance in C13K human ovarian cancer cells. Front. Genet. 9, 1–8 (2018).
  MedlineGoogle Scholar
• 75. Zhang Y, Huang S, Guo Y, Li L. MiR-1294 confers cisplatin resistance in ovarian cancer cells by targeting IGF1R. Biomed. Pharmacother. 106, 1357–1363 (2018).
  Medline CASGoogle Scholar
• 76. Moriwaki K, Chan FK-M. RIP3: a molecular switch for necrosis and inflammation. Genes Dev. 27(15), 1640–1649 (2013).
  Medline CASGoogle Scholar
• 77. Koo G-B, Morgan MJ, Lee D-G et al. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res. 25(6), 707–725 (2015).
  Medline CASGoogle Scholar
• 78. Park S-Y, Kang K-B, Thapa N, Kim S-Y, Lee S-J, Kim I-S. Requirement of adaptor protein GULP during stabilin-2-mediated cell corpse engulfment. J. Biol. Chem. 283(16), 10593–10600 (2008).
  Medline CASGoogle Scholar
• 79. Lee Y, Chen M, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor: new modes and prospects. Nat. Rev. Mol. Cell Biol. 19(9), 547–562 (2018).
  Medline CASGoogle Scholar
• 80. Ahuja N, Sharma AR, Baylin SB. Epigenetic therapeutics: a new weapon in the war against cancer. Annu. Rev. Med. 67, 73–89 (2016).
  Medline CASGoogle Scholar
• 81. Fu S, Hu W, Iyer R et al. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 117(8), 1661–1669 (2011).
  Medline CASGoogle Scholar
• 82. Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C. A Phase I and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer fang. Cancer 116(17), 4043–4053 (2010).
  Medline CASGoogle Scholar
• 83. Lu Y, Chan Y-T, Tan H-Y, Li S, Wang N, Feng Y. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Mol. Cancer 19(1), 79 (2020).
  MedlineGoogle Scholar
• 84. Tambo Y, Hosomi Y, Sakai H et al. Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small-cell lung cancer in patients previously treated with platinum-based chemotherapy. Invest. New Drugs 35(2), 217–226 (2017).
  Medline CASGoogle Scholar
• 85. Yardley DA, Ismail-Khan RR, Melichar B et al. Randomized Phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromata. J. Clin. Oncol. 31(17), 2128–2135 (2013).
  Medline CASGoogle Scholar
• 86. Overman MJ, Morris V, Moinova H et al. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget. 7(41), 67495–67506 (2016).
  MedlineGoogle Scholar
• 87. Matulonis U, Berlin S, Lee H et al. Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother. Pharmacol. 76(2), 417–423 (2015).
  Medline CASGoogle Scholar
• 88. Falchook GS, Fu S, Naing A et al. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest. New Drugs 31(5), (2013).
  Google Scholar
• 89. Reiman T, Savage KJ, Crump M et al. A Phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†. Leuk. Lymphoma 60(4), 912–919 (2019).
  Medline CASGoogle Scholar
• 90. Matei D, Fang F, Shen C et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res. 72(9), 2197–2205 (2012).
  Medline CASGoogle Scholar
• 91. Glasspool RM, Brown R, Gore ME et al. A randomised, Phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. Br. J. Cancer 110(8), 1923–1929 (2014).
  Medline CASGoogle Scholar
• 92. Coleman RL, Oza AM, Lorusso D et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet 390(10106), 1949–1961 (2017).
  Medline CASGoogle Scholar
• 93. Oza A, Matulonis U, Alvarez A, Roman L, Sarah Blagden SB et al. A randomized Phase 2 trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer. Clin. Cancer Res. 26(5), 1009–1016 (2020).
  Medline CASGoogle Scholar
• 94. Ummarino S, Hausman C, Di Ruscio A. The PARP way to epigenetic changes. Genes (Basel) 12(3), 1–16 (2021).
  Google Scholar
• 95. Tume L, Cisneros C, Sevillano J et al. Desregulación de microARN en el cáncer: un enfoque terapéutico y diagnóstico. Gac. Mex. Oncol. 15(5), 298–304 (2016).
  Google Scholar
• 96. Li S, Li Q, Lü J et al. Targeted inhibition of miR-221/222 promotes cell sensitivity to cisplatin in triple-negative breast cancer MDA-MB-231 cells. Front. Genet. 10 (2020).
  MedlineGoogle Scholar
• 97. Wang X, Zhang H, Bai M et al. Exosomes serve as nanoparticles to deliver anti-miR-214 to reverse chemoresistance to cisplatin in gastric cancer. Mol. Ther. 26(3), 774–783 (2018).
  Medline CASGoogle Scholar
• 98. Fathi Dizaji B. Strategies to target long noncoding RNAs in cancer treatment: progress and challenges. Egypt. J. Med. Hum. Genet. 21(1), 41 (2020).
  Google Scholar
• 99. Majchrzak-Celinska A, Warych A, Szoszkiewicz M. Novel approaches to epigenetic therapies: from drug combinations to epigenetic editing. Genes (Basel) 12(2), 1–21 (2021).
  Google Scholar
• 100. Appleton K, Mackay HJ, Judson I et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J. Clin. Oncol. 25(29), 4603–4609 (2007).
  Medline CASGoogle Scholar
• 101. Roberti A, Valdes AF, Torrecillas R, Fraga MF, Fernandez AF. Epigenetics in cancer therapy and nanomedicine. Clin. Epigenetics. 11(1), 1–18 (2019).
  MedlineGoogle Scholar
• 102. Buocikova V, Rios-Mondragon I, Pilalis E et al. Epigenetics in breast cancer therapy – new strategies and future nanomedicine perspectives. Cancers (Basel) 12(12), 1–32 (2020).
  Google Scholar
• 103. De Souza C, Ma Z, Lindstrom AR, Chatterji BP. Nanomaterials as potential transporters of HDAC inhibitors. Med. Drug Discov. 6(100040), 1–7 (2020).
  Google Scholar